Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Jaguar Health Inc JAGX

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.... see more

Current News (NDAQ:JAGX)

Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts

ACCESS Newswire 2 days ago

Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million

ACCESS Newswire 4 days ago

Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication

ACCESS Newswire 10 days ago

Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

ACCESS Newswire January 2, 2026

Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)

ACCESS Newswire December 15, 2025

FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs

ACCESS Newswire December 10, 2025

Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders

ACCESS Newswire December 8, 2025

Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study

ACCESS Newswire December 2, 2025

Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones

ACCESS Newswire November 24, 2025

Opinion & Analysis (NDAQ:JAGX)

No current opinion is available.

Bullboard Posts (NDAQ:JAGX)

Buy buddy buy.

Otherwise FOMO
coolfooldumbguy - 22 hours ago

Buy buddy buy because it's taking off this morning.

Otherwise FOMO
coolfooldumbguy - 5 days ago

JAGX....just goes to show u...ya can't give up !!!!

Even on a "train wreck" like this....up large on low volume and halted....Sheesh Make note : BTTR is a stock to watch...
Iseneschal - April 25, 2025

Jaguar Health, Inc. (NASDAQ:JAGX) – Diversifying into

http://beyondspx.com/2024/07/31/jaguar-health-inc-nasdaqjagx-diversifying-into-cancer-supportive-care-with-promising-rare-disease...
MikeTester - August 2, 2024

RE:JAGX. only 340million shares trade during reg hrs

I'll go out on a limb and say...... here comes a Reverse split announcement Mark this ; )
Iseneschal - March 4, 2024

JAGX. only 340million shares trade during reg hrs

Add 23 million more in AH Last NR was in Feb....   Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance ...
Iseneschal - March 4, 2024